HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Goes To Multi-Omics Data With Goal Of Personalizing Acne Intervention

Executive Summary

Unilever aims to use Onegevity’s AI and multi-omics database as a platform to develop “new diagnostic models that offer bespoke acne management regiments,” according to the New York-based health intelligence company’s announcement.

You may also be interested in...



Unilever Divests Dollar Shave Club, Focused On 30 ‘Power Brands’ Under New CEO’s Action Plan

More brands, particularly those acquired prior to Unilever’s 2019 shift in M&A strategy, could be on the chopping block, according to CEO Hein Schumacher, who took the helm in July. His targeted action plan includes investments to accelerate innovation and increase brand and marketing support.

Unilever Says Findings On Microbiome-Boosting Lipid Technology Will Fuel Product Innovation

Unilever’s research partnerships are paying off, yielding microbiome findings that are accelerating the firm’s innovation pipeline, with new products envisioned for treating scalp, underarms and oral health in addition to skin, the firm says.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel